These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9168442)

  • 1. Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma.
    Avilés A; Calva A; Díaz-Maqueo JC; Talavera A; Huerta-Guzmán J; Vásquez E
    Leuk Lymphoma; 1997 Apr; 25(3-4):319-25. PubMed ID: 9168442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
    Avilés A; Nambo MJ; Talavera A; Garcia EL; Huerta-Guzman J; Díaz Maqueo JC
    Anticancer Drugs; 1997 Nov; 8(10):937-42. PubMed ID: 9436636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
    Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14 +R) in high-risk diffuse large cell lymphoma.
    Avilés A; Nambo MJ; Neri N; Cleto S; Castañeda C; Huerta-Guzmàn J; Murillo E; Contreras M; Talavera A; González M
    Med Oncol; 2007; 24(1):85-9. PubMed ID: 17673816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
    Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
    Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma.
    Merli F; Bertini M; Luminari S; Mozzana R; Botto B; Liberati AM; Baldini L; Cabras G; Di Vito F; Orsucci L; Naglieri E; Polimeno G; Marcheselli L; Pennese E; Vitolo U; Federico M; Gallo E
    Leuk Lymphoma; 2007 Feb; 48(2):367-73. PubMed ID: 17325898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
    De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
    J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
    Avilés A; Nambo MJ; Neri N; Talavera A; Castañeda C; Murillo E; Cleto S; Huerta-Guzmán J
    Med Oncol; 2004; 21(3):269-72. PubMed ID: 15456955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
    Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
    Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage.
    Lee KW; Kim DY; Yun T; Kim DW; Kim TY; Yoon SS; Heo DS; Bang YJ; Park S; Kim BK; Kim NK
    Cancer; 2003 Dec; 98(12):2651-6. PubMed ID: 14669285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.
    Fridrik MA; Greil R; Hausmaninger H; Krieger O; Oppitz P; Stöger M; Klocker J; Neubauer M; Helm W; Pont J; Fazeny B; Hudec M; Simonitsch I; Radaszkiewicz T
    Ann Hematol; 1997 Oct; 75(4):135-40. PubMed ID: 9402845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
    Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
    Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
    Vitolo U; Liberati AM; Cabras MG; Federico M; Angelucci E; Baldini L; Boccomini C; Brugiatelli M; Calvi R; Ciccone G; Genua A; Deliliers GL; Levis A; Parvis G; Pavone E; Salvi F; Sborgia M; Gallo E;
    Haematologica; 2005 Jun; 90(6):793-801. PubMed ID: 15951292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
    Avilés A; Neri N; Castañeda C; Talavera A; Huerta-Guzmán J; González M
    Med Oncol; 2002; 19(1):55-8. PubMed ID: 12025891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
    Hertzberg M; Matthews JP; Stone JM; Dubosq MC; Grigg A; Ellis D; Benson W; Browett P; Horvath N; Januszewicz H; Abdi E; Green M; Bonaventura A; Marlton P; Cannell P; Wolf M;
    Am J Hematol; 2014 May; 89(5):536-41. PubMed ID: 24481640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
    Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma.
    Avilés A; Delgado S; Nambo MJ; Alatriste S; Díaz-Maqueo JC
    Int J Radiat Oncol Biol Phys; 1994 Nov; 30(4):799-803. PubMed ID: 7525515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
    Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
    Leuk Lymphoma; 1994 Sep; 15(1-2):153-7. PubMed ID: 7532056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.